![]() ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members. Disclaimer ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives. Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services. |
|
|||||||||||
Increased capsaicin-induced secondary hyperalgesia in patients with MCSSaturday 12 February 2011
Increased capsaicin-induced secondary hyperalgesia in patients with multiple chemical sensitivity. Abstract OBJECTIVE: the underlying cause of pathophysiological mechanisms triggering multiple chemical sensitivity (MCS) remains disputed. Recently, alterations in the central nervous system, for example, central sensitization, similar to various chronic pain disorders, have been suggested. Capsaicin is used in experimental pain models to provoke peripheral and central sensitization. In patients with symptoms elicited by odorous chemicals capsaicin-induced secondary hyperalgesia and temporal summation were assessed as markers for abnormal central nociceptive processing together with neurogenic inflammation (flare). METHODS: sixteen patients fulfilling Cullen criteria for MCS and 15 eczema patients with airway symptoms induced by odorous chemicals (EC) were compared with 29 age-matched healthy controls. Participants underwent 2 intradermal injection of capsaicin (3.3 mM and 33 mM). Measurements included pain intensity, flare, pinprick hyperalgesia, temporal summation, and McGill Pain Questionnaire score. RESULTS: no difference was found in the flare area between the groups. The capsaicin-evoked pain intensity was higher in MCS patients compared with controls (P<0.01, 33 mM). The area of secondary hyperalgesia was larger in both the patient groups compared with controls (P<0.05) at both capsaicin concentrations. Temporal summation was increased in MCS patients compared with controls (P<0.01). Further, in patients with comorbidity of fibromyalgia, pain and chronic fatigue, pain continued after end stimulation, and the stimulus response function was enhanced compared with patients without comorbidity, and significant to controls (P<0.05). CONCLUSION: this is the first study to show facilitated pain processing in MCS and EC patients with the most abnormal responses in MCS. PMID: 21268302 [PubMed - in process]
The above originally appeared here.
blog comments powered by Disqus |
||||||||||||
|
Registered Charity 3104
Email:
sacfs@sacfs.asn.au
Mailing address:
PO Box 322,
Modbury North,
South Australia 5092
Phone:
1300 128 339
Office Hours:
Monday - Friday,
10am - 4pm
(phone)